BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34120701)

  • 21. Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan.
    Mizumachi T; Homma A; Sakashita T; Kano S; Hatakeyama H; Fukuda S
    Int J Clin Oncol; 2017 Aug; 22(4):682-689. PubMed ID: 28271391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Implication of N1b Classification in the Eighth Edition of the Tumor-Node-Metastasis Staging System of Differentiated Thyroid Cancer.
    Kim M; Jeon MJ; Oh HS; Park S; Song DE; Sung TY; Kim TY; Chung KW; Kim WB; Shong YK; Lee YM; Kim WG
    Thyroid; 2018 Apr; 28(4):496-503. PubMed ID: 29620964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8 on staging of differentiated thyroid cancer: a comparison to version 7.
    Verburg FA; Mäder U; Luster M; Reiners C
    Clin Endocrinol (Oxf); 2018 Jun; 88(6):950-956. PubMed ID: 29573277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eighth edition of tumor-node-metastasis staging system improve survival predictability for papillary, but not follicular thyroid carcinoma: A multicenter cohort study.
    Kim M; Kim HI; Jeon MJ; Kim HK; Kim EH; Yi HS; Kim ES; Kim H; Kim BH; Kim TY; Kim SW; Kang HC; Kim WB; Chung JH; Shong YK; Kim TH; Kim WG
    Oral Oncol; 2018 Dec; 87():97-103. PubMed ID: 30527251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma.
    Nam SH; Bae MR; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2018 Dec; 87():158-164. PubMed ID: 30527232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modification of the Tumor-Node-Metastasis Staging System for Differentiated Thyroid Carcinoma by Considering Extra-Thyroidal Extension and Lateral Cervical Lymph Node Metastasis.
    Kim M; Kim WG; Jeon MJ; Kim HK; Yi HS; Kim ES; Kim BH; Kim WB; Shong YK; Kang HC; Kim TY
    Endocrinol Metab (Seoul); 2020 Mar; 35(1):149-156. PubMed ID: 32207275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refining the tumor-node-metastasis staging system for individualized treatment of differentiated thyroid carcinoma.
    Kim YN; Kim M; Ahn HS; Kim K; Park SY; Kim HI; Jeon MJ; Kim WG; Kim SW; Kim WB; Chung JH; Shong YK; Kim TY; Kim TH
    Oral Oncol; 2019 Feb; 89():8-13. PubMed ID: 30732964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
    Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stage II Differentiated Thyroid Cancer Is a High-Risk Disease in Patients <45/55 Years Old.
    Liu Z; Shen X; Liu R; Zhu G; Huang T; Xing M
    J Clin Endocrinol Metab; 2019 Nov; 104(11):4941-4948. PubMed ID: 31116377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems.
    Meng ZW; Pan W; Hong HJ; Chen JZ; Chen YL
    Medicine (Baltimore); 2017 Aug; 96(34):e7891. PubMed ID: 28834905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Validation of the Prognostic Stage Groups of the Eighth-Edition TNM Staging for Medullary Thyroid Carcinoma.
    Park SY; Cho YY; Kim HI; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Kim K; Kim SW; Chung JH; Kim TH
    J Clin Endocrinol Metab; 2018 Dec; 103(12):4609-4616. PubMed ID: 30137493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results (SEER) registry.
    Tran Cao HS; Johnston LE; Chang DC; Bouvet M
    Surgery; 2012 Aug; 152(2):145-51. PubMed ID: 22503316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients.
    Verburg FA; Mäder U; Tanase K; Thies ED; Diessl S; Buck AK; Luster M; Reiners C
    J Clin Endocrinol Metab; 2013 Jan; 98(1):172-80. PubMed ID: 23150687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TNM 8th edition in thyroid cancer staging: is there an improvement in predicting recurrence?
    Manzardo OA; Cellini M; Indirli R; Dolci A; Colombo P; Carrone F; Lavezzi E; Mantovani G; Mazziotti G; Arosio M; Lania AGA
    Endocr Relat Cancer; 2020 Jun; 27(6):325-336. PubMed ID: 32229701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modification of the eight-edition tumor-node-metastasis staging system with N1b for papillary thyroid carcinoma: A multi-institutional cohort study.
    Kim M; Kim HK; Kim HI; Kim EH; Jeon MJ; Yi HS; Kim ES; Kim H; Kim TH; Kim BH; Kim TY; Kang HC; Kim WB; Chung JH; Shong YK; Kim SW; Kim WG
    Oral Oncol; 2018 Nov; 86():48-52. PubMed ID: 30409319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stage migration with the new American Joint Committee on Cancer (AJCC) staging system (8th edition) for differentiated thyroid cancer.
    Shaha AR; Migliacci JC; Nixon IJ; Wang LY; Wong RJ; Morris LGT; Patel SG; Shah JP; Tuttle RM; Ganly I
    Surgery; 2019 Jan; 165(1):6-11. PubMed ID: 30415873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TUMOR SIZE IS AN INDEPENDENT PREDICTOR OF MORTALITY RISK IN DIFFERENTIATED THYROID CANCER PATIENTS WITH T4 DISEASE.
    Wang Z; Zhang Q; Ye H; Jia C; Lv Z; Liu J; Yin Z
    Endocr Pract; 2020 May; 26(5):499-507. PubMed ID: 31968190
    [No Abstract]   [Full Text] [Related]  

  • 38. No significant difference in the prognostic value of the 5th and 7th editions of AJCC staging for differentiated thyroid cancer.
    Vrachimis A; Gerss J; Stoyke M; Wittekind C; Maier T; Wenning C; Rahbar K; Schober O; Riemann B
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):911-7. PubMed ID: 24417487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in Stage Distribution and Disease-Specific Survival in Differentiated Thyroid Cancer with Transition to American Joint Committee on Cancer 8th Edition: A Systematic Review and Meta-Analysis.
    Lechner MG; Bernardo AC; Lampe A; Praw SS; Tam SH; Angell TE
    Oncologist; 2021 Feb; 26(2):e251-e260. PubMed ID: 32864832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impacts of the American Joint Committee on Cancer (AJCC) 8
    Thewjitcharoen Y; Chatchomchuan W; Karndumri K; Porramatikul S; Krittiyawong S; Wanothayaroj E; Butadej S; Nakasatien S; Veerasomboonsin V; Kanchanapituk A; Rajatanavin R; Himathongkam T
    Heliyon; 2021 Mar; 7(3):e06624. PubMed ID: 33869853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.